Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting ...
Inovio Pharmaceuticals, Inc. ( INO) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 25, 2026 12:40 PM EST ...
A San Diego high school senior is a finalist in the prestigious Regeneron Science Talent Search competition for her research ...
As universities increasingly adopt digital tools and automated analytics systems, attention often centers on these tools' ...
After a century of study, physicists have theories — but they’re still not 100% sure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results